ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

HS-20110

A development code. Also written as “HS-20110 in combination with bevacizumab, 5-fluorouracil (5-FU), and leucovorin.” and “HS-20110 in combination with bevacizumab, 5-FU, and leucovorin.”.

Its studies are led by Hansoh Pharmaceutical Group.

Furthest: phase 1, since Feb 24, 20251 company-led study, 1 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Group11 open or runningphase 1since Feb 24, 2025Feb 24, 2025Dec 31, 2026phase 1 · NCT06892379
  • Named in hoffmann la roche’s own pipeline as RG6975 CDH17 ADC (Hansoh), phase 1, as of Oct 22, 2026 (source).

Also a collaborator on its studies: Hoffmann-La Roche.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 24, 2025First study: phase 1 study in Solid TumorsFirst studyNCT06892379 · 631 planned · United States, China

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in Solid TumorsNCT06892379

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06892379Solid Tumors · United States, China1RecruitingDec 31, 2026631

How it is read

Names in the registry

  • “HS-20110”, 2 entries
  • “HS-20110 in combination with bevacizumab, 5-fluorouracil (5-FU), and leucovorin.”, 1 entry
  • “HS-20110 in combination with bevacizumab, 5-FU, and leucovorin.”, 1 entry

Codes read as this program: HS20110.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 21, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.